Mahesh Karande, President and CEO of Omega Therapeutics, describes the company’s systematic approach to using mRNA therapeutics as epigenetic medicines, with the ability to control abnormal gene expression in a range of diseases, as well as why so many “Omegans” have stayed with the company as it has grown. More from Flagship @ JPM2023 here.
Related Companies
- Omega Therapeutics Founded: 2017
